Announcement PDF RNS Number : 2902C Shield Therapeutics PLC 17 June 2021 Shield Therapeutics plc ("Shield" or the "Group" or the "Company") Results of 2021 Annual General Meeting London, UK, 17 June 2021: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol), announces the results of the voting for each of the resolutions as set out in the Notice of Annual General Meeting 2021. The Board reports that resolutions 1 to 10 passed as ordinary resolutions and resolutions 11 and 12 were passed as special resolutions, full details are shown below. The following table shows the votes cast on each resolution: Resolution 1 Resolution 2 Resolution 3 Resolution 4 Resolution 5 Resolution 6 Resolution 7 Resolution 8 Resolution 9 Resolution 10 Resolution 11 Resolution 12 VOTES FOR 115,096,905 115,083,904 115,083,904 115,927,366 115,086,905 115,082,443 115,083,904 115,114,781 115,956,508 115,905,527 115,719,269 114,882,135 % 99.94 99.2 99.2 99.93 99.2 99.2 99.2 99.2 99.93 99.91 99.75 99.03 VOTES AGAINST 6,544 866,271 866,271 25,810 866,271 867,732 866,271 866,695 27,207 47,834 228,432 1,065,566 % 0.01 0.75 0.75 0.02 0.75 0.75 0.75 0.75 0.02 0.04 0.2 0.92 VOTES WITHELD 883,488 36,762 36,762 36,761 36,761 36,762 36,762 5,461 3,222 33,576 39,236 39,236 Notes: 1. Number of shares in issue 215,837,965. 2. Details of the votes received on the resolutions are available on the Company's website: https://www.shieldtherapeutics.com/corporate-documents/. 3. Shield Therapeutics plc LEI: 213800G74QWY15FC3W71. For further information please contact: Shield Therapeutics plc www.shieldtherapeutics.com Greg Madison, CEO Lucy Huntington-Bailey (General Counsel and Company Secretary) Nominated Adviser and Joint Broker Peel Hunt LLP James Steel/Dr Christopher Golden Joint Broker finnCap Ltd Geoff Nash/Matt Radley/Alice Lane Financial PR & IR Advisor Walbrook PR Paul McManus/Lianne Cawthorne +44 (0)19 1511 8500 +44 (0)20 7418 8900 +44 (0)20 7220 0500 +44 (0)20 7933 8780 or shield@walbrookpr.com +44 (0)7980 541 893 / +44 (0)7584 391 303 About Shield Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru® /Accrufer® (ferric maltol), a novel, stable, nonsalt based oral therapy for adults with iron deficiency with or without anaemia. Shield's lead product, Feraccru®/Accrufer®, has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid2030s. The Group plans to launch Accrufer® in the US during 2021 through a highly experienced sales and marketing team. Feraccru® is already being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan. For more information, please visit www.shieldtherapeutics.com. Follow Shield on Twitter @ShieldTx This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END RAGMZGMVFNLGMZM